President Trump recently nominated Scott Gottlieb, a venture partner with New Enterprise Associates, to lead the U.S. Food and Drug Administration (FDA). This isn't terribly surprising, as we had previously noted that Gottlieb was the front-runner in a process that also included a pair of other folks with venture capital credentials (Jim O'Neill of Peter Thiel's Mithril and former Andreessen Horowitz partner Balaji Srinivasan).
Axios spoke with with David Mott, the former MedImmune CEO who now leads NEA's healthcare investing practice, for some thoughts on Gottlieb:
Selling point: Mott argues that Gottlieb was the best person for the job because he has a "360 degree" view of the healthcare system, given that he is a practicing physcian, has worked with healthcare entrepreneurs and investors via NEA, has been a paid consultant to big pharma, has worked in a medical academic institution, has past FDA (and CMS) experience and is a cancer survivor. In short, he understands the pressures each group is under.